Mon, May 5, 8:38 PM (10 days ago)
**IRADIMED CORPORATION (IRMD) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $19.5M (up 11% YoY) - **Net Income:** $4.7M (up 13% YoY) - **EPS (Diluted):** $0.37 (up 16% YoY) - **Gross Margin:** 76.1% (steady YoY) - **Operating Margin:** 27.9% (up from 27.0% YoY) - **Cash Flow from Operations:** $4.3M (up 11% YoY) **Key Metrics & Trends:** - **Revenue Growth:** Driven by increased sales of IV infusion pumps, disposables, and extended warranty agreements. - **Geographic Performance:** U.S. revenue up 19%, international revenue down 15%. - **Operating Expenses:** Increased by 9% YoY, primarily due to higher sales, marketing, and administrative costs. - **Cash Flow:** Positive operating cash flow, offset by higher capital expenditures and financing activities. **Uncertainties & Future Operations:** - **Trade Policies:** Potential impacts from U.S. and international trade policies, including tariffs. - **Regulatory Approvals:** Dependence on FDA and international regulatory clearances for products. - **Supply Chain:** Risks associated with key component availability and manufacturing disruptions. - **Economic Conditions:** Potential impacts from inflation, interest rates, and global economic uncertainties. **Outlook:** - **Revenue Growth:** Expected to continue due to increased demand for medical devices and products. - **Operating Expenses:** Anticipated to rise due to higher sales, marketing, and regulatory costs. - **Liquidity:** Strong cash position and access to financial markets for future needs. **Ticker:** IRMD